How much water do I add to Lenbelintide?

You can reconstitute Lenbelintide with 0.5, 1, or 2 mL of bacteriostatic water. Each option produces a different concentration and syringe draw for the same dose. Use the calculator to see which is easiest to measure.

What does Lenbelintide cost per dose?

Cost per dose depends on vial size, price paid, and your dose. Enter your vendor's price in the Lenbelintide calculator to see cost per dose and monthly cost.

What is the reference dose for Lenbelintide?

The commonly referenced range is Once weekly in trials; milligram dose levels have not been publicly disclosed, taken weekly. This is reference information, not a recommendation. Talk to a licensed clinician.

What are the side effects of Lenbelintide?

Reported side effects of Lenbelintide include: Stomach side effects.; Trial-only.. Severity and frequency vary by person and dose.

Who should not take Lenbelintide?

Lenbelintide is generally not appropriate for: Pregnancy or breastfeeding; Any prescription medicine you take regularly, without checking for interactions first; Anyone who wants established safety data, because none exists for this compound in humans. Talk to a licensed clinician before starting.

New?New to peptides?Start here →

Decoding

Lenbelintide_Dosage, benefits & legal status

Also known as AZD6234

By the Peptide Decoding Editorial Team

Published October 4, 2026

An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor.

Weight lossAmylin analogInvestigational

InAmylin analogsWeight loss

DoseOnce weekly in trials; milligram dose levels have not been publicly disclosed

FrequencyWeekly

RouteUnder the skin (subcutaneous)

StatusInvestigational

MixYour choice, calculate it

CycledNot cycled in the trials

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

See how this dose compares across the library →

What is Lenbelintide?

Plain language first. The technical label stays, but it never stands alone.

Overview

It copies the fullness hormone your pancreas makes, to reduce appetite, and is tuned to prefer the amylin receptor over the calcitonin receptor. It is still experimental.

The technical version

Lenbelintide is a long-acting, amylin-receptor-selective analog.

What it's used for

An experimental weekly shot that copies a natural fullness hormone to reduce appetite, designed to prefer the amylin receptor over the calcitonin receptor.

How does Lenbelintide work?

What it does in the body, and where.

Lenbelintide is a long-acting amylin copy built for selectivity: it favours the amylin receptor over the calcitonin receptor.

01
It works through amylin receptors
Fullness signalled through the brainstem rather than the gut-hormone route.
02
Built to be selective
It binds the amylin-3 (AMY3) receptor roughly 14 times more strongly than the calcitonin receptor, which is why AstraZeneca classifies it as a selective amylin receptor agonist rather than a dual agonist like petrelintide.
03
Still investigational
Phase 2 is ongoing. No approval anywhere.

Receptors

Acts on one receptor.

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Weight loss, positioned as a selective amylin-receptor optionInvestigational

The published record

Research index

Papers and trials about Lenbelintide

1 papers tagged human · 0 not reviews or lab · 0 clinical trial publications

1 registered trials · none with posted results

Compare this against the whole library →

Browse the records

In animals0

In the lab0

Reviews0

Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.

Compound field notes

At a glance

Four things to know about Lenbelintide

Evidence

Investigational

How much, and do you cycle it?

The range, and whether you take breaks.

Once weekly in trials; milligram dose levels have not been publicly disclosed, weekly. Not cycled in the trialsTrial dose

Given continuously for the whole study period, with the dose stepped up at the start, which is a ramp rather than a cycle.

Compare this against the whole library →

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)

Printed on the vial.

What you paid per vial

Used for cost per dose only.

Your dose (mg)

Commonly referenced range: The phase 2b trial lists three active dose groups and once-weekly injections, but does not disclose their milligram amounts. An earlier phase 1 study (NCT05511025) tested single subcutaneous doses of 0.3, 0.9, 1.5, 2.7, 3.0, and 4.2 mg. Those are study doses, not a dosing schedule, and no community convention has formed around this compound yet.Trial schedule

Choose your mix

Easiest0.5 mL water—units · 20 mg/mL

Half a 100-unit syringe

Easiest1 mL water—units · 10 mg/mL

One full 100-unit syringe

Easiest2 mL water—units · 5 mg/mL

Two full 100-unit syringes

Easiestyour own mL

units · —

Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units

Full calculator with reorder date →Read a syringe →

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized Lenbelintide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 16% charged residues, 41% hydrophobic. Acid may help.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.

Pregnancy or breastfeeding
Any prescription medicine you take regularly, without checking for interactions first
Anyone who wants established safety data, because none exists for this compound in humans

Stop and get help

These are emergencies. Seek care.

Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
Redness, heat, or pus at the injection site, which can signal infection
Any severe or unexpected symptom
Anything unusual, since there is no known safety profile to compare it against

Common effects

Expected, and usually mild.

Stomach side effects.
Trial-only.
Redness, soreness, or a small bump at the injection site
Beyond the above, unknown. There is no reliable human data on what this compound commonly causes

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

Is Lenbelintide approved?

And where the numbers on this page come from.

No. Lenbelintide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

Approval status
Investigational
Route
Under the skin (subcutaneous)
Checked
4 October 2026
Dose
From published clinical trials. Not approved by a regulator for this dose.
Vial size
From what vendors typically list; not a recommendation.
Sources
ClinicalTrials.gov, AZD6234 phase 1 single-ascending-dose study (NCT05511025)Frontiers in Endocrinology, obesity pipeline review Rauschecker et al., Obesity (ObesityWeek abstract)

What has happened recently

Still in trials. AstraZeneca is running phase 2 studies in obesity. It is not approved anywhere and long-term safety is unknown.

You can compare this against the whole library, or read how to check a seller.

What else is like Lenbelintide?

Others in Amylin analogs, side by side.

If you're weighing Lenbelintide, it's worth reading Petrelintide, Pramlintide, and Cagrilintide in the same class.

YOU ARE HERE

Lenbelintide

An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor.

Investigational

Dose: Once weekly in trials; milligram dose levels have not been publicly disclosed
How often: Weekly

PETRE

Petrelintide

An experimental weekly fullness-hormone shot for weight loss.

Investigational

Dose: 0.6 up to 9 mg per week (start low, increase slowly)
How often: Weekly

PRAM

Pramlintide

An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger.

FDA-approved

Dose: 0.015 up to 0.12 mg per dose (start low, increase slowly)
How often: With meals

CAGRI

Cagrilintide

A weekly fullness-hormone shot, often paired with semaglutide for bigger loss.

Investigational

Dose: 0.3 up to 4.5 mg per dose (start low, increase slowly)
How often: Weekly

Compare every amylin peptide

Guides for this compound

How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.

Sources

ClinicalTrials.gov, AZD6234 phase 1 single-ascending-dose study (NCT05511025)(2024)
Phase 1 randomized, single-blind, placebo-controlled study of AZD6234 in overweight or obese adults; 54 participants, completed December 2023.
Frontiers in Endocrinology, obesity pipeline review(2025)
Reports the single-ascending-dose study of AZD6234: single subcutaneous doses of 0.3, 0.9, 1.5, 2.7, 3.0, and 4.2 mg were studied. No weekly dose schedule has been published.
Rauschecker et al., Obesity (ObesityWeek abstract)(2024)
Abstract reporting safety, tolerability, and pharmacokinetics of AZD6234 from the single-ascending-dose study.

Beyond these, 1 records are indexed. Browse the records